Aldeyra Therapeutics resubmits NDA for reproxalap for DED signs and symptoms treatment

News
Article

Reproxalap was previously found to be statistically superior to vehicle for the primary endpoint of ocular discomfort (P=0.004) in a Phase 3 randomized, double-masked, vehicle-controlled dry eye chamber clinical trial.

Eye split between healthy and irritated Image credit: AdobeStock/AlessandroGrandini

Image credit: AdobeStock/AlessandroGrandini

Biotechnology company Aldeyra Therapeutics announced the resubmission of the New Drug Application (NDA) to the US FDA for the investigational new drug candidate topical ocular reproxalap, intended for the treatment of signs and symptoms of dry eye disease (DED).1 The application was resubmitted with a draft label reflecting acute activity in reducing dry eye symptoms in a dry eye chamber trial, chronic activity in reducing dry eye symptoms in a field trial, and acute activity in reducing ocular redness in 2 dry eye chamber trials, according to a news release. Previously disclosed positive results from a completed DED symptom trial were also submitted after being requested by the FDA following review of the previously submitted NDA.1

“If approved, reproxalap would have the potential to be the first DED therapy for chronic use with pivotal data demonstrating acute activity in reducing dry eye symptoms and ocular redness, 2 characteristics of dry eye disease of primary importance to patients,” said Todd C. Brady, MD, PhD, Aldeyra’s president and CEO, in the release.

Reproxalap is also in development for allergic conjunctivitis and works as a first-in-class small-molecule modulator of RASP, which are found to be elevated in ocular and systemic inflammatory diseases. The drug candidate has been studied in more than 2500 patients with no observed safety concerns, with mild and transient instillation site irritation as the most commonly reported adverse event in clinical trials assessing reproxalap.1

Aldeyra announced in August 2024 that the primary endpoint was met in a Phase 3 randomized, double-masked, vehicle-controlled dry eye chamber clinical trial assessing reproxalap in patients with DED. Reproxalap was found to be statistically superior to vehicle for the primary endpoint of ocular discomfort (P=0.004), which is acknowledged by the FDA as a symptom of DED, the release stated. Aldeyra also stated that it believes the results are supportive of the potential rapid clinical effect of reproxalap on reducing ocular discomfort as associated with DED.1

Per the Prescription Drug User Fee Act, the NDA resubmission is slated for FDA acknowledgement of acceptance for review within 30 days of submission, with completion of submission review to be completed within 6 months.1

Reference:
  1. Aldeyra Therapeutics resubmits reproxalap New Drug Application for the treatment of dry eye disease. News release. Aldeyra Therapeutics. October 3, 2024. Accessed October 3, 2024. https://ir.aldeyra.com/news-releases/news-release-details/aldeyra-therapeutics-resubmits-reproxalap-new-drug-application

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Drs Brianna Rhue and Diana Canto-Sims discuss the benefits of implementing a contact lens management system that can help improve lens sales at your practice.
Matt Jones, OD; Matt Burns, OD; and Joe Sugg, OD; detailed what optometrists can expect to change when HB 1353's regulations are enacted later this year.
Elise Kramer, OD, FAAO, FSLS, describes her take on a multidisciplinary approach to dry eye
Dana Shannon, OD, FAAO, shares pearls on spotting red flags in need of referral and enhancing patient care with follow-up compliance.
Dana Shannon, OD, FAAO, detailed a lecture she gave at the NOA Midwestern Symposium earlier this month.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, gave 2 presentations alongside other ODs and MDs at CRU 2025.
Melissa Tawa, OD, FAAO, provides insights to take glaucoma management from reactive to proactive in presentations given at CRU 2025 in Napa, California.
Rachelle Lin, OD, MS, FAAO, details her presentation on inherited retinal diseases at CRU 2025.
Jennifer Li, MD, details a talk she gave alongside Melissa Barnett, OD, FAAO, FSLS, FBCLA, at CRU 2025 in Napa, California.
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
© 2025 MJH Life Sciences

All rights reserved.